Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

Item
http://www.wikidata.org/entity/Q45752944
Viral hepatitis and hepatocellular carcinomaNew perspectives in occult hepatitis C virus infectionHepatitis C: a review for primary care physiciansAminoadamantanes versus other antiviral drugs for chronic hepatitis CAminoadamantanes for chronic hepatitis CAminoadamantanes versus other antiviral drugs for chronic hepatitis CAminoadamantanes for chronic hepatitis CInterferon for interferon nonresponding and relapsing patients with chronic hepatitis CRibavirin monotherapy for chronic hepatitis CRibavirin plus interferon versus interferon for chronic hepatitis CPharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeysSafety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety TrialChanges in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control studyTreatment of acute hepatitis C virus infection with interferon-alpha 2b and ribavirin: case report and review of the literaturePhysicians' preference values for hepatitis C health states and antiviral therapy: a surveyFast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C.Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 InfectionNext Steps Toward Eradication of Hepatitis C in the Era of Direct Acting AntiviralsChronic hepatitis C: This and the new era of treatmentResistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical ImplicationsEra of direct acting antivirals in chronic hepatitis C: Who will benefit?Hepatitis C virus (HCV) infection in Africa: a reviewEmerging therapies for the treatment of hepatitis CDisruption of Bcl-2 and Bcl-xL by viral proteins as a possible cause of cancerElevated Concentration of Defensins in Hepatitis C Virus-Infected PatientsReplication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay.Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy.Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer.Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapyConservation of the Conformation and Positive Charges of Hepatitis C Virus E2 Envelope Glycoprotein Hypervariable Region 1 Points to a Role in Cell AttachmentHepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response.Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity.Production and Characterization of Monoclonal Antibodies Specific for a Conserved Epitope within Hepatitis C Virus Hypervariable Region 1Performance characteristics of the COBAS Amplicor Hepatitis C Virus (HCV) Monitor, Version 2.0, International Unit assay and the National Genetics Institute HCV Superquant assayPerformance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay.Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcomeChronic viral hepatitis C: management updateDetection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system.Evaluation of the VERSANT HCV RNA 3.0 assay for quantification of hepatitis C virus RNA in serum
P2860
Q21245597-32F394A4-22C3-4723-9AAE-E3A722D11D30Q22305491-874FAA3C-9A1A-4116-BE2A-C7550A5A9C5FQ22306040-45906E61-C78C-44C4-89CC-4D5F71980F37Q24193940-06320159-3FE0-4E77-A6C0-899C672AE2FAQ24194770-8701B83A-B3B3-4DFE-BAB8-AE2E11ECF3FEQ24194815-7A471A7E-DDD9-40CC-9BBB-35EC4BCCB5D0Q24201226-2FFB31AF-139D-4FA7-B0EB-317254ED9054Q24201588-BC86A0E1-75DF-4683-98D4-6E629DB996C3Q24240057-0A35B359-C5DA-4177-B084-C66C07AD30FFQ24240879-7BF9E3BB-9571-4316-BFFF-D42BAD669538Q24680380-57DCA4E4-B9FC-4727-9DBF-5BB8DE03FA89Q24683611-F8ED2D89-AFCE-4FD0-BC28-AD5E1DD140C7Q24797971-8753A8C2-6A7A-428B-AD45-CD4CFF05CF08Q24799021-8536F03F-A579-4EBF-862E-AF7AE30A8A65Q24802683-5CA45E9E-C542-40EF-B6BE-8C45A3B0154BQ24804388-DBBF402F-70BD-4D98-956D-C5762B5E826AQ24813993-C6502D8E-CA10-4428-821A-1F4C0BF84764Q26746563-4C6CD43A-09D0-4455-8465-F0ED7BE92EE9Q26747561-47EBD0F6-81E9-4B17-8540-C6E8A05C9AB9Q26775011-7D02DCEF-E1F2-45E0-94BF-DCED41ABA98AQ26777408-22BB21BA-F103-454A-8413-08FCC42731BCQ26777506-717B011C-D1DB-4DEB-8426-C83F79D89080Q26824322-7444142D-440A-4F2A-98DA-354CCDA40D57Q27003319-275A288A-C5D7-4B45-B498-B27635E1C1ECQ27020978-9D0BA3C1-321B-4CC1-ADD4-D1FE8BAC33AFQ27469045-DFFDDE97-5F5D-4152-AD10-C13D39182117Q27469483-7627439D-7C67-489B-A5D6-0A1E24B1FF62Q27469620-E9AF57E9-5AE0-48F7-B5FC-CCB81A427CE6Q27469698-2E054C02-6449-4065-B113-0B80A442A349Q27469719-E2E7AA20-5B21-45A9-BDB5-847A5BD8EF17Q27469804-C140CAE3-6FE6-455E-A59D-20ACE24E1638Q27469808-B6857A81-BDDB-444B-9E4D-62C459DE9476Q27469851-6B7285D4-4908-4903-854E-8F164E906BD2Q27470002-4D016590-E9F4-4F49-9310-8FB866B9C74AQ27471191-DE8F47ED-0E23-4A92-B65B-98BA8F81ABE3Q27471213-6BDB1A6A-ED95-4D6D-B5B9-664462446A56Q27471683-E13346C3-F34E-4BF8-89E8-7D5A2F2D5B8BQ27471844-D36F703E-2B1F-42FD-B01F-0A4DF15BF8C0Q27472717-25BC0672-A34D-42B6-8900-E51335BA5FA4Q27472747-43FB148C-B450-4FC4-B8B2-CB12191DD029
P2860

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

Item
http://www.wikidata.org/entity/Q45752944
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Randomised trial of interferon ...... nterventional Therapy Group (I
@en
Randomised trial of interferon ...... s Interventional Therapy Group
@nl
type
label
Randomised trial of interferon ...... nterventional Therapy Group (I
@en
Randomised trial of interferon ...... s Interventional Therapy Group
@nl
prefLabel
Randomised trial of interferon ...... nterventional Therapy Group (I
@en
Randomised trial of interferon ...... s Interventional Therapy Group
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Randomised trial of interferon ...... nterventional Therapy Group (I
@en
P2093
P304
P31
P356
10.1016/S0140-6736(98)07124-4
P407
P433
P478
P50
P577
P698
P921